Bristol-Myers Squibb stock jumps on schizophrenia drug approval
WEB8 hours ago · Bristol-Myers Squibb shares rose in premarket trade on Friday after the U.S. Food and Drug Administration approved a schizophrenia drug.
Bristol Myers Squibb Stock Rises After Schizophrenia
WEB3 hours ago · Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia...
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB18 hours ago · Bristol Myers Squibb expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October, executives told CNBC. The drug is a badly needed new option...
FDA approves Bristol Myers Squibb's new schizophrenia drug
WEB2 hours ago · The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the ...
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval …
WEB5 hours ago · Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.
U.S. Food and Drug Administration Approves Bristol Myers …
WEB16 hours ago · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB6 hours ago · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a f...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug …
WEB18 hours ago · Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
Bristol Myers Squibb - News
WEBSep 10, 2024 · Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
WEBMar 18, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).